Page 67 - Drug Class Review
P. 67
Drug Effectiveness Review Project
Drugs Authors: Agid et al. 56 Country: Multinational Novartis Pharma AG To investigate the efficacy and tolerability of two different dosages of RIV in elderly patients with Setting: Multi-center (Europe, 54 centers) placebo rivastigmine rivastigmine N/A 6 mg/d 4 mg/d 13 weeks 13 weeks 13 weeks 133 133 136 Diagnosis of mild-to-moderate dementia using DSM-IV and DSM-III-R criteria and diagnosis of probable AD according to NINCDS/ADRDA criteria Medications for non-cognitive aspects of AD such as hypnotics provided they were not long-acting agents; drugs for other co
Alzheimer Year: 1998 probable AD Study design: RCT Sample size: 402 NR
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
